Reversal of PCP-induced learning and memory deficits in the Morris’ water maze by sertindole and other antipsychotics
- First Online:
- 303 Downloads
In humans, the N-methyl-d-aspartate antagonist phencyclidine (PCP) induces behavioral changes that mimic schizophrenia symptoms, including positive and negative symptoms as well as cognitive deficits. In clinic, the cognitive deficits are closely associated with functional outcome. Thus, improvement of cognition may have high impact on patients’ daily life.
In the present study, three second-generation antipsychotics (sertindole, risperidone, and clozapine) as well as the classical antipsychotic haloperidol were tested for the ability to reverse PCP-induced cognitive deficits in the Morris’ water maze.
The second-generation antipsychotics reversed the PCP-induced cognitive impairment: sertindole (0.63–2.5 mg/kg, s.c.), risperidone (0.04 mg/kg, s.c.; whereas 0.08 and 0.16 mg/kg were without significant effect), and clozapine (0.63 mg/kg, s.c.; while 1.3 mg/kg was without significant effect). The significant effect of sertindole was observed from day 2 onwards, while clozapine and risperidone only had significant effect at day 3. The classical antipsychotic haloperidol (0.010–0.020 mg/kg, s.c.) was ineffective. No compounds influenced swimming speed at the doses used, indicating that motor function was preserved.
These results confirm that repeated PCP administration induces marked cognitive deficits. Further, second-generation antipsychotics like sertindole, clozapine, and risperidone within a certain, often narrow, dose range are able to reverse the impairment and thus might improve cognitive deficits in schizophrenic patients, whereas classical compounds like haloperidol lack this effect. The receptor mechanisms involved in the reversal of PCP’s disruptive effect are discussed and likely include a delicate balance between effects on dopamine D2, 5-HT2A/6, alpha-adrenergic, muscarinic, and histaminergic H1 receptors.
KeywordsSchizophrenia Cognition Rat Phencyclidine Antipsychotic Receptor profile
- Hirst W, Stean T, Rogers D, Sunter D, Pugh P, Moss S, Bromidge S, Riley G, Smith D, Bartlett S, Heidbreder C, Atkins A, Lacroix L, Dawson L, Foley A, Regan C, Upton N (2006) SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 553:109–119PubMedCrossRefGoogle Scholar
- Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wilkowitz O, Csernansky JG (1996) The effect of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 15:361–369PubMedCrossRefGoogle Scholar
- Leysen JE (2000) Receptor profile of antipsychotics. In: Ellenbroek BA, Cools AR (eds) Atypical antipsychotics. Milestones in drug therapy. Birkhäuser Verlag, Basel, pp 57–81Google Scholar
- Nuechterlein KH, Robbins TW, Einat H (2005) Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr Bull 31:870–874PubMedCrossRefGoogle Scholar
- Rodefer JS, Nguyen TN, Arnt J (2006) The effects of antipsychotics on cognitive deficits produced by subchronic PCP administration in a rodent attentional ED/ID set-shifting task. Int J Neuropsychopharmacol 9(S1):S140Google Scholar
- Siegel S (1956) Nonparametric statistics for the behavioral sciences. McGraw-Hill, New YorkGoogle Scholar
- Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177:207–216PubMedCrossRefGoogle Scholar